Answers are grounded in this paper and cite their sources.
Tirzepatide treatment was associated with improved self-reported HRQoL outcomes compared with placebo among people with obesity or overweight with T2D. Participants achieving greater bodyweight reductions and those with physical function limitations at baseline showed greater improvements in HRQoL. CLINICAL TRIAL REGISTRATION NUMBER FOR SURMOUNT-2: NCT04657003.
No takes yet. Share an insight, caveat, or question.
Hunter et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: